DEVELOP CGMP TECHNOLOGY FOR CRISPR/CAS GENOME EDITING OF CELLS FOR USE IN CELL-BASED IMMUNOTHERAPY FOR CANCER

NIH RePORTER · NIH · N01 · $4,033,134 · view on reporter.nih.gov ↗

Abstract

Support to develop cGMP manufacturing capability for non-viral, genome editing of immune cells for use in cancer cell therapy indications.

Key facts

NIH application ID: 10281320
Project number: 75N91019D00024-0-759102000017-1
Recipient: LEIDOS BIOMEDICAL RESEARCH, INC.
Principal Investigator: ETHAN DMITROVSKY
Activity code: N01
Funding institute: NIH
Fiscal year: 2020
Award amount: $4,033,134
Award type: —
Project period: 2020-09-25 → 2023-09-24